FamGenix vs Phenotips: an honest comparison

This page is a head-to-head comparison of FamGenix and Phenotips. Teams searching "famgenix vs phenotips" usually want a plain-English summary of which is the better fit for their service. That is what this page provides. Evagene is briefly introduced at the end as a third option; this article is genuinely about FamGenix and Phenotips first. All product claims are drawn from each vendor's public website and documentation as of April 2026.

Short version. Choose FamGenix if your service is cancer genetics and you value breadth of cancer risk models (BOADICEA v6, Tyrer-Cuzick v8, BayesMendel variants, Gail, Claus, QRISK3) run simultaneously on a single family history, with regional data tailored to US/CA/UK-EU/AU and NCCN-aligned workflow — FamGenix is the product most explicitly built for that. Choose Phenotips if your service is phenotype-driven rare disease diagnostics with HPO at the centre, you need a genomic health record platform with broader scope than cancer risk, and global deployment with GDPR/DSPT/HIPAA/CE+ certifications matters. They solve different problems well.

How FamGenix and Phenotips position themselves

FamGenix is a modern cancer-risk-first pedigree platform that launched in 2021. Its headline is breadth of risk models on one family history: BOADICEA v6 (the current CanRisk engine for breast and ovarian cancer), Tyrer-Cuzick v8, several BayesMendel family members, Gail (breast), Claus (breast), and QRISK3 (cardiovascular risk, used in some UK settings alongside cancer screening decisions). Running these models simultaneously on the same family history — not forcing the clinician to re-enter data per model — is a real workflow advantage in cancer genetics. FamGenix also supports regional data for the US, Canada, UK/EU, and Australia, which matters for region-specific incidence rates and screening guideline alignment. Its customer reference set includes 4 of the top 10 US cancer centres. It is HIPAA and GINA compliant. A free Individual tier is available; institutional tiers are priced separately.

Phenotips is a broader genomic health record platform whose centre of gravity is HPO-driven phenotype capture aimed at rare disease diagnostic yield ("up to 30x faster"). Its installed base spans 100,000+ patient records across 60+ countries, with 500+ specialists per its homepage. Public certifications include GDPR, DSPT, HIPAA, and CE+; design is LGBTQIA+-inclusive; ownership is Gene42 / Think Research. Its published Research Team plan is $399/month for 5 users plus $25 per additional user; clinic and hospital tiers are priced on application.

The products look similar on the surface — both are modern, web-based clinical genetics platforms — but they solve different problems. FamGenix asks "what's this family's cancer risk across the best-available models, and what should we do about it?" Phenotips asks "what rare disease does this phenotype suggest, and which candidate genes should we prioritise?"

Feature comparison

The matrix below compares features each vendor publishes. A tick means the capability is publicly advertised; a dash means it is not publicly listed. Evagene appears as a third column.

Matrix compiled from publicly available product pages and documentation as of April 2026. "—" indicates the capability is not publicly advertised and does not necessarily mean it is absent.

Cancer-risk breadth vs phenotype-driven diagnostics

The cleanest way to understand the choice is to imagine a cancer genetics clinic and a rare disease diagnostic clinic side by side. The cancer genetics clinic wants to know whether a family's history suggests they meet NCCN testing criteria, whether a patient's breast cancer risk exceeds the threshold for enhanced surveillance, whether Tyrer-Cuzick and BOADICEA agree, and whether the Gail model's lifetime risk aligns with what BayesMendel says. FamGenix is designed so all of those answers come off a single pedigree without re-entering data. Its customer list — 4 of the top 10 US cancer centres — is exactly who buys that capability.

The rare disease diagnostic clinic wants to take a child's phenotype, code it against HPO, see which genes and syndromes the combination suggests, and use that prioritisation to guide variant interpretation from a sequencing result. Phenotips is designed for that loop. Its 60+ country footprint and broad certification set match institutions whose rare disease programme operates within a larger genomic medicine service.

Neither product is wrong for its target; they are both right for different targets. If you are trying to decide which fits, the question is not "which is better" but "which problem are you trying to solve?"

Regional data and screening guideline alignment

FamGenix's regional data support (US, Canada, UK/EU, Australia) is a less-publicised but important capability. Cancer incidence rates vary meaningfully by region, and NICE/NCCN/local guideline thresholds for enhanced surveillance or risk-reducing intervention differ. A model like Tyrer-Cuzick run with US incidence data will give a numerically different answer than the same model run with UK data, even for the same family history. FamGenix's regionalisation is built to align the numbers with the guideline the clinician actually uses. For cross-border or UK-and-US-both clinics, this is a practical advantage.

Phenotips's global deployment is a different kind of capability: one platform that works across jurisdictions, with certifications passing multiple regulatory regimes. It is not specifically aligned to region-by-region risk model parameterisation, because that is not its primary clinical use case.

AI, integration, and modern tooling

Neither FamGenix nor Phenotips publicly advertises LLM-based AI clinical interpretation or a bring-your-own-key AI model today. Phenotips's intelligence is its HPO-to-gene suggestion pipeline; FamGenix's intelligence is its risk-model stack. These are valuable capabilities, but they are different from the "assistant drafts the clinical report from the pedigree" pattern that is emerging across clinical software.

On integration surface, neither product publishes a developer-facing REST API or webhooks at the depth a platform-first vendor would. EHR integration is the main integration story for both, negotiated in the sales motion. For services building AI agents or custom integrations against the pedigree, neither product is the obvious fit.

Pricing and procurement

FamGenix's free Individual tier is a differentiator — individuals exploring their own family history can use it at no cost, which also gives clinics a way to trial the product's drawing UX before procurement. Institutional tiers are priced separately and obtained via quote.

Phenotips's Research Team plan is publicly priced at $399/month for 5 users (+$25/user additional), which is approximately $4,788/year entry-tier for a small research team. Clinic and hospital tiers are priced on application.

Both run institutional procurement motions. Neither publishes full pricing. Budget planning should include a vendor quote.

When to choose FamGenix

• Your service is cancer genetics and you value breadth of risk models (BOADICEA v6, Tyrer-Cuzick v8, BayesMendel variants, Gail, Claus, QRISK3) run simultaneously on one family history.
• You want NCCN-criterion-aligned workflow and regional data for the US, Canada, UK/EU, or Australia.
• Your institution's peers include the top 10 US cancer centres and you value being on a platform that those peers use.
• You want a free Individual tier for patient self-use or for low-friction clinician trials before procurement.
• HIPAA and GINA are your compliance priorities.

When to choose Phenotips

• Your service is phenotype-driven rare disease diagnostics and HPO capture is central.
• You need a broad genomic health record platform, not just a pedigree or cancer-risk tool.
• Global deployment matters and you want advertised GDPR/DSPT/HIPAA/CE+ certifications.
• LGBTQIA+-inclusive design is a priority.
• You are comfortable with partial public pricing ($399/month for the research tier) and an enterprise quote motion for clinic tiers.

A third option to consider: Evagene

FamGenix and Phenotips are both strong products for their respective centres of gravity. For services whose requirements include modern AI integration, a public REST API, and an MCP server for AI agents — capabilities neither FamGenix nor Phenotips publicly prioritises — Evagene is worth evaluating alongside them.

Evagene is a browser-based clinical pedigree management platform with gesture drawing, a 200+ disease catalogue coded to ICD-10 and OMIM, integrated BayesMendel cancer risk models (BRCAPRO, MMRpro, PancPRO), Mendelian inheritance analysis for AD/AR/XR patterns, karyogram viewing, and consanguinity detection via Wright's coefficient. Evagene's cancer risk model coverage is narrower than FamGenix's — if your service depends on BOADICEA v6 or Tyrer-Cuzick v8 specifically, FamGenix is a better fit today — but Evagene covers the core BayesMendel set cleanly.

Evagene's AI layer is bring-your-own-key: the service provides its own Anthropic Claude or OpenAI GPT credentials, encrypted at rest with Fernet, and clinical text flows directly to the model provider the service has already risk-assessed. Analysis Templates let a service codify its house style of report writing. The MCP server exposes 11 pedigree tools to Claude Desktop, Claude Code, and any other MCP-compatible AI agent. The integration surface comprises a scoped, rate-limited REST API with SHA-256-hashed keys, HMAC-SHA256-signed webhooks, and an embeddable pedigree viewer.

Evagene is in Alpha and free via waiting list at evagene.com. It does not replace FamGenix's cancer-risk-breadth or Phenotips's HPO-first rare disease depth for services that need those today. It offers a credible modern alternative for services whose priorities are AI and programmable access.

Frequently asked questions

Related reading

• FamGenix vs Evagene
• Phenotips vs Evagene
• FamGenix vs Progeny
• Phenotips vs Progeny
• Pedigree drawing software: a practical guide
• All Evagene comparisons